-
公开(公告)号：EP1924603A2
公开(公告)日：2008-05-28
申请号：EP06814491.4
申请日：2006-09-13
申请人： Zymogenetics, Inc.
发明人： THOMPSON, Penny, J. , SIADAK, Anthony, W. , NORIEGA, Claire, R. , FRANKLIN, Henry, R. , OGUZ, Secil , THOMPSON, Deborah, L. , TOPOUZIS, Stavros , FRUEBIS, Joachim , BRASEL, Kenneth , YAO, Yue
IPC分类号： C07K16/18 , C07K14/47 , A61K39/395
CPC分类号： C07K14/4702 , A61K2039/505 , C07K16/22 , C07K2317/76
摘要： The present invention provides methods of using PROK2 and PROK1 antagonist, including monoclonal antibodies to treat inflammation, angiogenesis, and cancer.
-
2.发明公开ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 有权抗IL-22RA抗体及其使用炎症结合对象和方法
公开(公告)号：EP1812476A1
公开(公告)日：2007-08-01
申请号：EP05816060.7
申请日：2005-10-21
申请人： ZymoGenetics, Inc.
发明人： XU, Wenfeng , KINDSVOGEL, Wayne, R. , CHANDRASEKHER, Yasmin, A. , DILLON, Stacey, R. , LEHNER, Joyce, M. , SIADAK, Anthony, W. , SIVAKUMAR, Pallavur, V. , MOORE, Margaret, D.
IPC分类号： C07K16/28 , C07K14/715
CPC分类号： C07K16/244 , A61K49/0008 , A61K2039/505 , C07K16/2866 , C07K2319/30 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
-
3.发明公开ANTI-IL-20 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 有权抗IL-20抗体和结合伴侣AND METHOD FOR USE炎症
公开(公告)号：EP1692180A2
公开(公告)日：2006-08-23
申请号：EP04811735.2
申请日：2004-11-19
申请人： ZymoGenetics, Inc.
发明人： XU, Wenfeng , KINDSVOGEL, Wayne, R. , CHEN, Zhi , HUGHES, Steven, D. , CHANDRASEKHER, Yasmin, A. , DILLON, Stacey, R. , LEHNER, Joyce, M. , SIADAK, Anthony, W. , SIVAKUMAR, Pallavur, V. , MOORE, Margaret, D.
CPC分类号： C07K16/2866 , A61K38/1793 , A61K38/20 , A61K47/60 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.
-
4.发明授权ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 有权抗IL-22RA抗体及其使用炎症结合对象和方法
公开(公告)号：EP1812476B1
公开(公告)日：2010-07-21
申请号：EP05816060.7
申请日：2005-10-21
申请人： ZymoGenetics, Inc.
发明人： XU, Wenfeng , KINDSVOGEL, Wayne, R. , CHANDRASEKHER, Yasmin, A. , DILLON, Stacey, R. , LEHNER, Joyce, M. , SIADAK, Anthony, W. , SIVAKUMAR, Pallavur, V. , MOORE, Margaret, D.
IPC分类号： C07K16/28 , C07K14/715
CPC分类号： C07K16/244 , A61K49/0008 , A61K2039/505 , C07K16/2866 , C07K2319/30 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
-
5.发明授权ANTI-IL-20 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 有权ANTI-IL-20-ANTIKÖRPERUND BINDUNGSPARTNER UND VERFAHREN ZUR ANWENDUNG BEIENTZÜNDUNGEN
公开(公告)号：EP1692180B1
公开(公告)日：2009-11-04
申请号：EP04811735.2
申请日：2004-11-19
申请人： ZymoGenetics, Inc.
发明人： XU, Wenfeng , KINDSVOGEL, Wayne, R. , CHEN, Zhi , HUGHES, Steven, D. , CHANDRASEKHER, Yasmin, A. , DILLON, Stacey, R. , LEHNER, Joyce, M. , SIADAK, Anthony, W. , SIVAKUMAR, Pallavur, V. , MOORE, Margaret, D.
CPC分类号： C07K16/2866 , A61K38/1793 , A61K38/20 , A61K47/60 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.
摘要翻译： 提供了可以与由选自以下的杂交瘤表达的单克隆抗体竞争与SEQ ID NO：2或3的多肽结合的结合多肽：（a）杂交瘤克隆262.4.1.2.2.1（ATCC [PTA-5350]）; （b）杂交瘤克隆262.5.1.6.4.4（ATCC [PTA-5351]）; 和（c）杂交瘤克隆262.7.1.3.2.4（ATCC [PTA-5352]）。
-
6.发明公开IL-31 MONOCLONAL ANTIBODIES AND METHODS OF USE 审中-公开MONOKLONALE IL-31-ANTIKÖRPERUND ANWENDUNGSVERFAHREN
公开(公告)号：EP1891111A1
公开(公告)日：2008-02-27
申请号：EP06752420.7
申请日：2006-05-08
申请人： ZymoGenetics, Inc.
发明人： SIADAK, Anthony, W. , BILSBOROUGH, Janine , FLORKIEWICZ, Elin , HARAN, Aaron, C. , RENE, Shirley
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C07K2317/92 , Y10S514/885 , Y10S514/886
摘要： There is provided a monoclonal antibody wherein the monoclonal antibody is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from a first group consisting of: a) ATCC Patent Deposit Designation PTA-6815; b) ATCC Patent Deposit Designation PTA-6816; c) ATCC Patent Deposit Designation PTA-6871; d) ATCC Patent Deposit Designation PTA-6829; and e) ATCC Patent Deposit Designation PTA-6830; or wherein the monoclonal antibody is selected from a second group consisting of: a) ATCC Patent Deposit Designation PTA-6831; b) ATCC Patent Deposit Designation PTA-6872; c) ATCC Patent Deposit Designation PTA-6875; and d) ATCC Patent Deposit Designation PTA-6873; for use in treating a disease selected from the group consisting of prurigo nodularis; cutaneous T cell lymphoma; atopic dermatitis; contact dermatitis; drug-induced allergic reactions; skin-tropic viruses; viral associated pruritis; vitiligo; alopecia aerata; acne rosacea; acne vulgaris; and bullous pemphigoid.
摘要翻译： 提供单克隆抗体，其中单克隆抗体由保藏有美国典型培养物保藏中心的杂交瘤产生，所述杂交瘤具有选自以下的第一组的ATCC专利保藏名称：a）ATCC专利保藏名称PTA-6815; b）ATCC专利保藏号PTA-6816; c）ATCC专利保藏号PTA-6871; d）ATCC专利保藏号PTA-6829; 和e）ATCC专利保藏号PTA-6830; 或其中所述单克隆抗体选自由以下组成的第二组：a）ATCC专利保藏名称PTA-6831; b）ATCC专利保藏号PTA-6872; c）ATCC专利保藏名称PTA-6875; 和d）ATCC专利保藏号PTA-6873; 用于治疗选自结节性痒疹的疾病; 皮肤T细胞淋巴瘤; 特应性皮炎; 接触性皮炎; 药物引起的过敏反应; 皮肤热带病毒; 病毒性相关性瘙痒症 白癜风; 秃头症 痤疮性红斑痤疮 寻常痤疮 和大疱性类天疱疮。
-
7.发明公开VARIABLE REGION SEQUENCES OF IL-31 MONOCLONAL ANTIBODIES AND METHODS OF USE 审中-公开单克隆抗体的可变区序列对IL-31和使用方法
公开(公告)号：EP2061811A2
公开(公告)日：2009-05-27
申请号：EP07814672.7
申请日：2007-09-04
申请人： ZymoGenetics, Inc.
IPC分类号： C07K16/24 , A61K39/395 , C12N5/18 , A61P37/00 , A61P17/00
CPC分类号： A61K39/3955 , A61K2039/505 , C07K16/244 , C07K2316/96 , C07K2317/14 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C12N5/0602
摘要： There is provided an isolated monoclonal antibody or antigen-binding fragment thereof that competes with the monoclonal antibody produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6815 for binding to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2; wherein the monoclonal antibody has a human IgG4 heavy chain immunoglobulin constant domain or wherein the antigen-binding fragment further comprises a human IgG4 heavy chain immunoglobulin constant domain; and wherein the monoclonal antibody or antigen-binding fragment inhibits signal transduction induced by the polypeptide through its heterodimeric receptor.
摘要翻译： 本发明提供分离的单克隆抗体或其抗原结合片段，其确实与由与具有ATCC专利保藏PTA-6815结合的多肽的氨基酸残基27由......组成美国典型培养物保藏中心保藏的杂交瘤细胞产生的单克隆抗体竞争 SEQ ID NO -164：2; worin单克隆抗体具有人IgG4重链免疫球蛋白恒定结构域或worin抗原结合片段还包含人IgG4重链免疫球蛋白恒定结构域; 和worin的单克隆抗体或其抗原结合片段抑制通过其异二聚体受体诱导多肽的信号转导。
-
8.发明公开ANTI-IL-20 RECEPTOR ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 审中-公开抗IL-20受体抗体及其使用炎症结合对象和方法
公开(公告)号：EP1697418A2
公开(公告)日：2006-09-06
申请号：EP04811758.4
申请日：2004-11-19
申请人： ZymoGenetics, Inc.
发明人： XU, Wenfeng , KINDSVOGEL, Wayne, R. , CHEN, Zhi , HUGHES, Steven, D. , CHANDRASEKHER, Yasmin, A. , DILLON, Stacey, R. , LEHNER, Joyce, M. , SIADAK, Anthony, W. , SIVAKUMAR, Pallavur, V. , MOORE, Margaret, D.
CPC分类号： C07K16/2866 , A61K38/1793 , A61K38/20 , A61K47/60 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking the activity of IL-20 receptor polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 receptor antibodies and binding partners, including anti-IL-20RA, anti-IL-20RB and anti-IL-20RA/IL-20RB antibodies as well as methods for antagonizing IL-20RA and IL-20RB, either individually or together, using such antibodies and binding partners.
摘要翻译： 本发明提供一种结合多肽做可以结合SEQ ID NO：2的多肽竞争：从所述组包括选择2或3与由杂交瘤表达的单克隆抗体：（a）所述的杂交瘤克隆262.4.1.2.2.1（ATCC [PTA-5350]）; （B）的杂交瘤克隆262.5.1.6.4.4（ATCC [PTA-5351]）; 和（c）杂交瘤克隆262.7.1.3.2.4（ATCC [PTA-5352]）。
-
9.发明授权ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 无效抗IL-22RA抗体和结合FOR USE启明创投与方法
公开(公告)号：EP1606317B1
公开(公告)日：2010-07-28
申请号：EP04749427.3
申请日：2004-03-24
申请人： ZymoGenetics, Inc.
发明人： XU, Wenfeng , KINDSVOGEL, Wayne , CHANDRASEKHER, Yasmin, A. , DILLON, Stacey, R. , LEHNER, Joyce, M. , SIADAK, Anthony, W. , SIVAKUMAR, Pallavur, V. , MOORE, Margaret, D.
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/34 , C07K2317/73 , C07K2319/00 , C07K2319/30
摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
-
10.发明公开ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 无效抗IL-22RA抗体和结合FOR USE启明创投与方法
公开(公告)号：EP1606317A2
公开(公告)日：2005-12-21
申请号：EP04749427.3
申请日：2004-03-24
申请人： ZymoGenetics, Inc.
发明人： XU, Wenfeng , KINDSVOGEL, Wayne , CHANDRASEKHER, Yasmin, A. , DILLON, Stacey, R. , LEHNER, Joyce, M. , SIADAK, Anthony, W. , SIVAKUMAR, Pallavur, V. , MOORE, Margaret, D.
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/34 , C07K2317/73 , C07K2319/00 , C07K2319/30
摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.034 秒)
